Importantly, the PIK3CA mutations and BRAF mutations, occurring in cases with wild-type KRAS, are known to be mechanistically activating and are enriched in other tumour types (Fig. 4f and Supplementary Figs 27–30). This evidence concerns the gene BRAF and neoplasm.